Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib

We herein report a case of the beneficial effect of osimertinib readministration in non-small-cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation. A 69-year-old non-smoking woman was diagnosed with advanced NSCLC harboring an EGFR exon19 deletion and T790M. She was...

Descripción completa

Detalles Bibliográficos
Autores principales: Makimoto, Go, Ohashi, Kadoaki, Senoo, Satoru, Hotta, Katsuyuki, Maeda, Yoshinobu, Kiura, Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599916/
https://www.ncbi.nlm.nih.gov/pubmed/30713295
http://dx.doi.org/10.2169/internalmedicine.2152-18
_version_ 1783431012849549312
author Makimoto, Go
Ohashi, Kadoaki
Senoo, Satoru
Hotta, Katsuyuki
Maeda, Yoshinobu
Kiura, Katsuyuki
author_facet Makimoto, Go
Ohashi, Kadoaki
Senoo, Satoru
Hotta, Katsuyuki
Maeda, Yoshinobu
Kiura, Katsuyuki
author_sort Makimoto, Go
collection PubMed
description We herein report a case of the beneficial effect of osimertinib readministration in non-small-cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation. A 69-year-old non-smoking woman was diagnosed with advanced NSCLC harboring an EGFR exon19 deletion and T790M. She was treated with osimertinib for two years but eventually acquired resistance. After 1.5 years of salvage chemotherapies, osimertinib was re-administered. She has been effectively and safely treated with osimertinib readministration for over 10 months. A prospective study is warranted to evaluate the efficacy and safety of osimertinib readministration in NSCLC with EGFR mutations.
format Online
Article
Text
id pubmed-6599916
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-65999162019-07-01 Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib Makimoto, Go Ohashi, Kadoaki Senoo, Satoru Hotta, Katsuyuki Maeda, Yoshinobu Kiura, Katsuyuki Intern Med Case Report We herein report a case of the beneficial effect of osimertinib readministration in non-small-cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation. A 69-year-old non-smoking woman was diagnosed with advanced NSCLC harboring an EGFR exon19 deletion and T790M. She was treated with osimertinib for two years but eventually acquired resistance. After 1.5 years of salvage chemotherapies, osimertinib was re-administered. She has been effectively and safely treated with osimertinib readministration for over 10 months. A prospective study is warranted to evaluate the efficacy and safety of osimertinib readministration in NSCLC with EGFR mutations. The Japanese Society of Internal Medicine 2019-02-01 2019-06-01 /pmc/articles/PMC6599916/ /pubmed/30713295 http://dx.doi.org/10.2169/internalmedicine.2152-18 Text en Copyright © 2019 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Makimoto, Go
Ohashi, Kadoaki
Senoo, Satoru
Hotta, Katsuyuki
Maeda, Yoshinobu
Kiura, Katsuyuki
Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib
title Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib
title_full Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib
title_fullStr Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib
title_full_unstemmed Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib
title_short Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib
title_sort beneficial effect of osimertinib readministration in non-small-cell lung cancer harboring an epidermal growth factor receptor (egfr) mutation with a history of acquired resistance to osimertinib
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599916/
https://www.ncbi.nlm.nih.gov/pubmed/30713295
http://dx.doi.org/10.2169/internalmedicine.2152-18
work_keys_str_mv AT makimotogo beneficialeffectofosimertinibreadministrationinnonsmallcelllungcancerharboringanepidermalgrowthfactorreceptoregfrmutationwithahistoryofacquiredresistancetoosimertinib
AT ohashikadoaki beneficialeffectofosimertinibreadministrationinnonsmallcelllungcancerharboringanepidermalgrowthfactorreceptoregfrmutationwithahistoryofacquiredresistancetoosimertinib
AT senoosatoru beneficialeffectofosimertinibreadministrationinnonsmallcelllungcancerharboringanepidermalgrowthfactorreceptoregfrmutationwithahistoryofacquiredresistancetoosimertinib
AT hottakatsuyuki beneficialeffectofosimertinibreadministrationinnonsmallcelllungcancerharboringanepidermalgrowthfactorreceptoregfrmutationwithahistoryofacquiredresistancetoosimertinib
AT maedayoshinobu beneficialeffectofosimertinibreadministrationinnonsmallcelllungcancerharboringanepidermalgrowthfactorreceptoregfrmutationwithahistoryofacquiredresistancetoosimertinib
AT kiurakatsuyuki beneficialeffectofosimertinibreadministrationinnonsmallcelllungcancerharboringanepidermalgrowthfactorreceptoregfrmutationwithahistoryofacquiredresistancetoosimertinib

Ejemplares similares